Get started
Denali Therapeutics Inc.Denali Therapeutics Inc.Denali Therapeutics Inc.

Denali Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

DNLI chart

Key stats

Market capitalization
‪2.54 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.05USD
Net income
‪−145.22 M‬USD
Revenue
‪330.53 M‬USD
Shares float
‪112.29 M‬
Beta (1Y)
2.46

About Denali Therapeutics Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
Ryan J. Watts
Website
denalitherapeutics.com
Headquarters
San Francisco
Employees (FY)
445
Founded
2013
ISIN
US24823R1059
FIGI
BBG008P7F869
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of DNLI is 17.84 USD — it has decreased by 2.30% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Denali Therapeutics Inc. stocks are traded under the ticker DNLI.
Denali Therapeutics Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Denali Therapeutics Inc. has a max estimate of 95.00 USD and a min estimate of 24.00 USD.
DNLI earnings for the last quarter are −0.72 USD whereas the estimation was −0.81 USD which accounts for 11.09% surprise. Estimated earnings for the next quarter are −0.80 USD. See more details about Denali Therapeutics Inc. earnings.
Denali Therapeutics Inc. revenue for the last quarter amounts to ‪1.27 M‬ USD despite the estimated figure of ‪11.16 M‬ USD. In the next quarter revenue is expected to reach ‪7.98 M‬ USD.
Yes, you can track Denali Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, DNLI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Denali Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
DNLI reached its all-time high on Dec 22, 2020 with the price of 93.94 USD, and its all-time low was 12.32 USD and was reached on Jul 31, 2018.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 445.00 employees. See our rating of the largest employees — is Denali Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Denali Therapeutics Inc. EBITDA is ‪−181.78 M‬ USD, and current EBITDA margin is −54.45%. See more stats in Denali Therapeutics Inc. financial statements.